LAVCA VC
  • News Feed
  • VC Data
  • Directories
  • Features
  • Tech Growth Coalition
  • LAVCA Gender Diversity
  • Engage
    • VC Council
    • VC Members
  • LAVCA
  • Member Login
  • Member Access

LAVCA VC

  • News Feed
  • VC Data
  • Directories
  • Features
  • Tech Growth Coalition
  • LAVCA Gender Diversity
  • Engage
    • VC Council
    • VC Members
  • LAVCA

DNA Capital, Temasek and Fit Participações Lead ~USD20m Round for Brazilian Healthtech Memed

November 1, 2021
DNA Capital + Memed

DNA Capital, Temasek and Fit Participacoes led a ~USD20m round extension for Memed, a Brazilian provider of digital drug prescriptions. DNA Capital led a ~USD60m round in July through a dedicated vehicle for the transaction with capital from undisclosed family offices and sovereign wealth funds. Qualcomm Ventures, Redpoint eventures and monashees exited Memed through a secondary sale to DNA Capital in May. 

(LABS News) – Brazilian health tech Memed has announced a new BRL 100 million funding round co-led by venture capital and private equity manager DNA Capital, Singapore-based global investment firm Temasek, and Fit Participações.

The investment is an extension of the round announced in June when DNA Capital raised an exclusive fund of BRL 300 million to acquire the stake of the company’s shareholders and assume control of the business. At the time, Redpoint Eventures, Qualcomm Ventures, and Monashees exited the startup.

The decision to allocate 100% of a fund’s resources to a single company shows the momentum of the health-tech sector and the potential attributed to Memed, a platform that brings together services for doctors, patients, pharmacies, and other participants in the health ecosystem.

At the time, Luiz Henrique Noronha, DNA Capital’s partner, explained that Memed’s ace in the hole is to develop technologies that benefit all players in the health sector. “With this fund, we will provide Memed with capital to continue its growth journey and stay at the forefront of product development for medical records, telemedicine services, and hospitals,” he said.

The flagship product of Memed, founded in 2012 by Ricardo Moraes, Rafael Moraes, René Moraes, and Marcel Ribeiro, is its digital prescription platform, which serves more than 250 healthcare companies in Brazil and is used by about 150,000 doctors, managing 2.7 million prescriptions per month. According to the company, in the last 12 months, the volume of digital prescriptions on its platform has grown by 400%. In addition to prescriptions, Memed has also developed a kind of marketplace for medicines and exams with more than 60,000 items.

Most of the funds from this new round will be invested to scale the product, technology, and clinical intelligence areas to enhance the experience of all players in the healthcare ecosystem who engage with the company.

“This round will allow us to generate more value for our partners, whether doctors, operators, insurers, cooperatives, hospitals, telemedicine players, as well as for the more than 2.2 million unique patients who benefit from Memed’s technology every month, whether for purchasing medications or scheduling exams,” said Joel Rennó Jr, Memed’s CEO.

DNA Capital, Temasek and Fit Participações Lead ~USD20m Round for Brazilian Healthtech Memed was last modified: November 2nd, 2021 by cramos
DNA CapitalFit ParticipacoesHealthtechTemasekVenture Capital
0
Facebook Twitter Google +

Categories

  • Deals
  • Exits
  • Regulatory
  • M&A
  • New Funds & Firms
  • Partnerships

Sign up for LAVCA’s bi-weekly Latin American Private Capital Update and the LatAm Venture Bulletin, produced specifically for venture investors, entrepreneurs, and technology startups in the early stage ecosystem.






Which LAVCA Newsletter would you like to receive?

Tweets

  • LAVCA's Associate Director of Research Emanuel Hernandez and Executive Director @naitafur explain trends in regiona… https://t.co/jMIUJfa6KZ

    16-May-2022

    Reply Retweet Favorite
  • Today's top takeaways from the #LatAmVentureBulletin: https://t.co/TdVT3WZ6YT

    12-May-2022

    Reply Retweet Favorite
  • Despite the political challenges in Latin America, LAVCA's Executive Director @naitafur, highlights that the privat… https://t.co/DiI1dGwFGr

    10-May-2022

    Reply Retweet Favorite
  • Notable USD100m+ rounds from LAVCA's Q1 2022 Preliminary Data include: @KeoWorld led by @HayfinCapital, @timeneon l… https://t.co/58wUihIowm

    05-May-2022

    Reply Retweet Favorite
  • LAVCA's Q1 2022 preliminary data recorded a total of USD2.7b invested across 157 transactions, making it the fourth… https://t.co/pDqfft6T9N

    03-May-2022

    Reply Retweet Favorite

Keep in touch

Twitter Linkedin Youtube

About LAVCA

 

LAVCA is the Association for Private Capital Investment in Latin America, a not-for-profit membership organization dedicated to supporting the growth of private capital in Latin America and the Caribbean through research, education, networking and advocacy.

LAVCA Office

    New York City:
    589 8th Ave, 18th Floor
    New York, NY 10018

Explore LAVCA.org

  • About LAVCA
  • Board, Team, & Advisors
  • Media
  • Contact Us
  • Membership Benefits
  • Members Only Access
  • Education and Programs
  • Research
  • Policy
  • LAVCA VC
  • Contact Us

@2020 - LAVCA. All Rights Reserved.


Back To Top